[Congenital Factor Ⅶ Deficiency: a Retrospective Analysis of 43 Cases]

Overview

Journal Zhonghua Xue Ye Xue Za Zhi

Specialty Hematology

Date 2020 Jun 16

PMID 32536136

Authors

C Y Qu

D L Zhang

X F Liu

F Xue

W Liu

Y F Chen

R F Fu

L Zhang

R C Yang

Affiliations

Soon will be listed here.

Abstract

To explore the pathogenesis, clinical characteristics, laboratory findings, diagnosis, treatment, and prognosis of congenital factor Ⅶ (FⅦ) deficiency. Clinical data of 43 patients with congenital FⅦ deficiency diagnosed from April 1999 to September 2019 were retrospectively analyzed. There were 27 females and 16 males. Median age was 16 (1-70) years. Family history was found in 6 cases. There were 29 (67.4%) cases with bleeding symptoms, most common of which were mucocutaneous bleeding (13 cases, 30.2%) , oral bleeding (13 cases, 30.2%) , and epistaxis (9 cases, 20.9%) . Menorrhagia occurred in 11 cases (47.6% of female patients who were in fertile age) . Laboratory findings were characterized by significantly prolonged prothrombin time (PT) , normal partial thromboplastin time (APTT) , and decreased FⅦ activity (FⅦ∶C) . Ten cases received gene mutation analysis and 3 new mutations were found. Fourteen cases (32.6%) were treated with prothrombin complex concentrates (PCC) , 12 (27.9%) with fresh frozen plasma (FFP) , and 3 (7.0%) with human recombinant activated FⅦ (rFⅦa) . Twenty cases (46.5%) with no or mild bleeding symptoms did not receive any replacement therapy. Previous bleeding symptoms recurred in 5 patients (11.6%) , 8 females still had heavy menstrual bleeding, and 9 patients (20.9%) were lost to follow-up. Most patients with congenital FⅦ deficiency have mild or no bleeding symptoms, but have a tendency to excessive bleeding after surgery or trauma. There is no significant correlation between FⅦ∶C and severity of bleeding symptoms. Prophylaxis should be applied in patients with severe bleeding symptoms and rFⅦa is the first choice. Gene mutation test is significant for screening, diagnosis, and prognosis prediction of the disease.

References

Voils S, Baird B . Systematic review: 3-factor versus 4-factor prothrombin complex concentrate for warfarin reversal: does it matter?. Thromb Res. 2012; 130(6):833-40. DOI: 10.1016/j.thromres.2012.10.001. View

Ruiz-Saez A . Occurrence of thrombosis in rare bleeding disorders. Semin Thromb Hemost. 2013; 39(6):684-92. DOI: 10.1055/s-0033-1353391. View

Tengborn L, Blomback M, Berntorp E . Tranexamic acid--an old drug still going strong and making a revival. Thromb Res. 2015; 135(2):231-42. DOI: 10.1016/j.thromres.2014.11.012. View

Palla R, Peyvandi F, Shapiro A . Rare bleeding disorders: diagnosis and treatment. Blood. 2015; 125(13):2052-61. DOI: 10.1182/blood-2014-08-532820. View

Jain S, Donkin J, Frey M, Peltier S, Gunawardena S, Cooper D . Phenotypical variability in congenital FVII deficiency follows the ISTH-SSC severity classification guidelines: a review with illustrative examples from the clinic. J Blood Med. 2018; 9:211-218. PMC: 6250109. DOI: 10.2147/JBM.S157633. View

Sevenet P, Kaczor D, Depasse F . Factor VII Deficiency: From Basics to Clinical Laboratory Diagnosis and Patient Management. Clin Appl Thromb Hemost. 2016; 23(7):703-710. DOI: 10.1177/1076029616670257. View

Napolitano M, Dolce A, Celenza G, Grandone E, Perilli M, Siragusa S . Iron-dependent erythropoiesis in women with excessive menstrual blood losses and women with normal menses. Ann Hematol. 2013; 93(4):557-63. DOI: 10.1007/s00277-013-1901-3. View

Borhany M, Boijout H, Pellequer J, Shamsi T, Moulis G, Aguilar-Martinez P . Genotype and phenotype relationships in 10 Pakistani unrelated patients with inherited factor VII deficiency. Haemophilia. 2013; 19(6):893-7. DOI: 10.1111/hae.12186. View

Rajpurkar M, Cooper D . Continuous infusion of recombinant activated factor VII: a review of data in congenital hemophilia with inhibitors and congenital factor VII deficiency. J Blood Med. 2018; 9:227-239. PMC: 6276614. DOI: 10.2147/JBM.S184040. View

10.

Baumann Kreuziger L, Morton C, Reding M . Is prophylaxis required for delivery in women with factor VII deficiency?. Haemophilia. 2013; 19(6):827-32. PMC: 3769463. DOI: 10.1111/hae.12167. View

11.

Hellstern P . Production and composition of prothrombin complex concentrates: correlation between composition and therapeutic efficiency. Thromb Res. 1999; 95(4 Suppl 1):S7-12. DOI: 10.1016/s0049-3848(99)00078-x. View

12.

Napolitano M, Giansily-Blaizot M, Dolce A, Schved J, Auerswald G, Ingerslev J . Prophylaxis in congenital factor VII deficiency: indications, efficacy and safety. Results from the Seven Treatment Evaluation Registry (STER). Haematologica. 2013; 98(4):538-44. PMC: 3659984. DOI: 10.3324/haematol.2012.074039. View

13.

Napolitano M, Di Minno M, Batorova A, Dolce A, Giansily-Blaizot M, Ingerslev J . Women with congenital factor VII deficiency: clinical phenotype and treatment options from two international studies. Haemophilia. 2016; 22(5):752-9. DOI: 10.1111/hae.12978. View

14.

Rodriguez-Merchan E . Fibrin glue for local haemostasis in haemophilia surgery. Hosp Pract (1995). 2017; 45(5):187-191. DOI: 10.1080/21548331.2017.1384689. View

15.

Quintavalle G, Riccardi F, Rivolta G, Martorana D, Di Perna C, Percesepe A . F7 gene variants modulate protein levels in a large cohort of patients with factor VII deficiency. Results from a genotype-phenotype study. Thromb Haemost. 2017; 117(8):1455-1464. DOI: 10.1160/TH17-02-0085. View

16.

Menegatti M, Peyvandi F . Treatment of rare factor deficiencies other than hemophilia. Blood. 2018; 133(5):415-424. DOI: 10.1182/blood-2018-06-820738. View